Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]
Roche Announces PathAI Collaboration for Artificial Intelligence-based Digital Pathology Applications for Improved Patient Care
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, […]
Roche Opens Access to Pathology Imaging Tools to Improve Patient Care
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the introduction of the Roche Digital Pathology Open […]
First Monoclonal Antibody Treatment for COVID-19 Approved for Use in the UK
Following on from a thorough review of the evidence carried out by the MHRA, and […]
Roche Receives FDA Approval for First Companion Diagnostic to Identify dMMR Solid Tumour Patients Eligible for Anti-PD-1 Immunotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval […]
FDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
New Data for Roche’s Hemlibra Reinforce Safety Profile in People with Haemophilia A
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the […]
Roche’s ENSPRYNG Approved by European Commission as First and Only At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved […]
New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new interim data from two studies of […]
New Data Shows AbbVie's VENCLYXTO/VENCLEXTA Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more